Literature DB >> 1933245

Ageing and Parkinson's disease: substantia nigra regional selectivity.

J M Fearnley1, A J Lees.   

Abstract

The micro-architecture of the substantia nigra was studied in control cases of varying age and patients with parkinsonism. A single 7 mu section stained with haematoxylin and eosin was examined at a specific level within the caudal nigra using strict criteria. The pars compacta was divided into a ventral and a dorsal tier, and each tier was further subdivided into 3 regions. In 36 control cases there was a linear fallout of pigmented neurons with advancing age in the pars compacta of the caudal substantia nigra at a rate of 4.7% per decade. Regionally, the lateral ventral tier was relatively spared (2.1% loss per decade) compared with the medial ventral tier (5.4%) and the dorsal tier (6.9%). In 20 Parkinson's disease (PD) cases of varying disease duration there was an exponential loss of pigmented neurons with a 45% loss in the first decade. Regionally, the pattern was opposite to ageing. Loss was greatest in the lateral ventral tier (average loss 91%) followed by the medial ventral tier (71%) and the dorsal tier (56%). The presymptomatic phase of PD from the onset of neuronal loss was estimated to be about 5 yrs. This phase is represented by incidental Lewy body cases: individuals who die without clinical signs of PD or dementia, but who are found to have Lewy bodies at post-mortem. In 7 cases cell loss was confined to the lateral ventral tier (average loss 52%) congruent with the lateral ventral selectivity of symptomatic PD. It was calculated that at the onset of symptoms there was a 68% cell loss in the lateral ventral tier and a 48% loss in the caudal nigra as a whole. The regional selectivity of PD is relatively specific. In 15 cases of striatonigral degeneration the distribution of cell loss was similar, but the loss in the dorsal tier was greater than PD by 21%. In 14 cases of Steele-Richardson-Olszewski syndrome (SRO) there was no predilection for the lateral ventral tier, but a tendency to involve the medial nigra and spare the lateral. These findings suggest that age-related attrition of pigmented nigral cells is not an important factor in the pathogenesis of PD.

Entities:  

Mesh:

Year:  1991        PMID: 1933245     DOI: 10.1093/brain/114.5.2283

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  877 in total

1.  The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.

Authors:  M A Hely; J G Morris; R Traficante; W G Reid; D J O'Sullivan; P M Williamson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease.

Authors:  K Dujardin; A Duhamel; E Becquet; C Grunberg; L Defebvre; A Destee
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

3.  Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.

Authors:  J O Rinne; H Ruottinen; J Bergman; M Haaparanta; P Sonninen; O Solin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

4.  Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease.

Authors:  A Hartmann; S Hunot; P P Michel; M P Muriel; S Vyas; B A Faucheux; A Mouatt-Prigent; H Turmel; A Srinivasan; M Ruberg; G I Evan; Y Agid; E C Hirsch
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 5.  Progressive supranuclear palsy (Steele-Richardson-Olszewski disease).

Authors:  H R Morris; N W Wood; A J Lees
Journal:  Postgrad Med J       Date:  1999-10       Impact factor: 2.401

6.  Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects.

Authors:  M Periquet; C Lücking; J Vaughan; V Bonifati; A Dürr; G De Michele; M Horstink; M Farrer; S N Illarioshkin; P Pollak; M Borg; C Brefel-Courbon; P Denefle; G Meco; T Gasser; M M Breteler; N Wood; Y Agid; A Brice
Journal:  Am J Hum Genet       Date:  2001-02-14       Impact factor: 11.025

Review 7.  Multiple system atrophy: pathophysiology and management.

Authors:  G K Wenning; S Braune
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

8.  Real-time monitoring of superoxide generation and cytotoxicity in neuroblastoma mitochondria induced by 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline.

Authors:  Sarah Jayne Boulton; Paul C Keane; Christopher M Morris; Calum J McNeil; Philip Manning
Journal:  Redox Rep       Date:  2012-05-30       Impact factor: 4.412

9.  Amygdala pathology in Parkinson's disease.

Authors:  H Braak; E Braak; D Yilmazer; R A de Vos; E N Jansen; J Bohl; K Jellinger
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 10.  Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.

Authors:  Xiaojun Guan; Xiaojun Xu; Minming Zhang
Journal:  Neurosci Bull       Date:  2017-05-17       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.